ARAV Stock Overview
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Aravive, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.79 |
| 52 Week High | US$2.40 |
| 52 Week Low | US$0.58 |
| Beta | 2.37 |
| 1 Month Change | 35.61% |
| 3 Month Change | 4.68% |
| 1 Year Change | -17.13% |
| 3 Year Change | -81.39% |
| 5 Year Change | -83.65% |
| Change since IPO | -99.05% |
Recent News & Updates
Recent updates
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Sep 03
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully
May 15Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Nov 06Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Jun 25Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?
Mar 18Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Feb 09
Shareholder Returns
| ARAV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.7% | 0.8% | 2.8% |
| 1Y | -17.1% | 7.1% | -9.2% |
Return vs Industry: ARAV underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: ARAV underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| ARAV volatility | |
|---|---|
| ARAV Average Weekly Movement | 19.0% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ARAV is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: ARAV's weekly volatility has increased from 13% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 23 | Gail McIntyre | https://aravive.com |
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway.
Aravive, Inc. Fundamentals Summary
| ARAV fundamental statistics | |
|---|---|
| Market Cap | US$107.09m |
| Earnings (TTM) | -US$60.15m |
| Revenue (TTM) | US$8.65m |
12.4x
P/S Ratio-1.8x
P/E RatioIs ARAV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARAV income statement (TTM) | |
|---|---|
| Revenue | US$8.65m |
| Cost of Revenue | US$61.18m |
| Gross Profit | -US$52.53m |
| Other Expenses | US$7.62m |
| Earnings | -US$60.15m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | -607.44% |
| Net Profit Margin | -695.57% |
| Debt/Equity Ratio | 0% |
How did ARAV perform over the long term?
See historical performance and comparison